Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer

Clinical Cancer Research

Volumn 14, Issue 1, 2008, Pages 224-229

  Sabichi, Anita L ^a   Lerner, Seth P ^b   Atkinson, E Neely ^a   Grossman, H Barton ^a   Caraway, Nancy P ^a   Dinney, Colin P ^a   Penson, David F ^c   Matin, Surena ^a   Kamat, Ashish ^a   Pisters, Louis L ^a   Lin, Daniel W ^d   Katz, Ruth L ^a   Brenner, Dean E ^e   Hemstreet III, George P ^f   Wargo, Mary ^a   Bleyer, Archie ^a   Sanders, William H ^g   Clifford, John L ^h   Parnes, Howard L ⁱ   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g Atlanta Regional Community Clinical Oncology Program Research Group   (United States)

^h LOUISIANA STATE UNIVERSITY   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; FENRETINIDE; PLACEBO;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NIGHT BLINDNESS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; FEMALE; FENRETINIDE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLACEBOS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 40749096451     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0733     Document Type: Article

References (56)

1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
2. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-30.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5; discussion 475-7.
4. Dinney CPN, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-6.
5. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
6. Sengupta S, Blute ML. The management of superficial transitional cell carcinoma of the bladder. Urology 2006;67:48-54.
7. Lerner SP. Treatment of high-risk, non-muscle-invasive bladder cancer. Natl Clin Pract Urol 2006;3:398-9.
8. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994;12:851-73.
9. Sabichi AL, Lippman SM. Chemoprevention of superficial bladder cancer. In: Textbook of Bladder Cancer, Lerner S, Schoenberg M, Sternberg C, editors. Chapter 39. London: Taylor and Francis Group; 2006. p. 403-10.
10. Kelloff GJ, Boone CW, Malone WF, et al. Development of chemopreventive agents for bladder cancer. J Cell Biochem Suppl 1992;16I:1-12.
11. Moon RC, McCormic DL, Becci PJ, et al. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis 1982;3:1469-72.
12. Moon RC, Detrisac CJ, Thomas CF, et al. Chemoprevention of experimental bladder cancer. J Cell Biochem 1992;161:134-8.
13. Hicks RM, Turton JA, Chowaniec J, et al. Modulation of carcinogenesis in the urinary bladder by retinoids. Ciba Found Symp 1985;113:168-90.
14. Sabichi AL, Lerner SP, Grossman HB, et al. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol 1998;10:479-84.
15. Hultin TA, May CM, Moon RC. N-(4-hydroxyphenyl)-all- transretinamide pharmacokinetics in female rats and mice. Drug Metab Dispos 1986;14:714-7.
16. Waliszewski P, Waliszewska M, Gordon N, et al. Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells. Mol Cell Endocrinol 1999;148:55-65.
17. Lotan R. Retinoid and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995;87:1655-7.
18. Sabichi AL, Hendricks DT, Bober MA, et al. Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 1998;90:597-605.
19. Formelli F, Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993;53:5374-6.
20. Oridate N, Lotan D, Xu XC, et al. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 1996;2:855-63.
21. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-56.
22. De Palo G, Veronesi U, Camerini T, et al. Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 1995;87:146-7.
23. Chiesa F, Tradati N, Marazza M, et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem 1993;17F:255-61.
24. Kelloff GJ, Crowell JA, Boone CW, et al. Clinical development plan: N-(4-hydroxyphenyl) retinamide. J Cell Biochem Suppl 1994;20:176-96.
25. Alfthan O, Tarkkanen J, Grohn P, et al. Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. Eur Urol 1983;9:6-9.
26. Studer UE, Jenzer S, Biedermann C, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995;28:284-90.
27. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-42.
28. Costa A, Formelli F, Chiesa F, et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994;54:2032-7s.
29. Lan KKG, DeMets D. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
30. Pang AS, Morales A. Chemoimmunoprophylaxis of an experimental bladder cancer with retinoids and Bacillus Calmette Guerin. J Urol 1983;130:166-70.
31. Mayne ST, Lippman SM. Cigarettes: a smoking gun in cancer chemoprevention. J Natl Cancer Inst 2005;97:1319-21.
32. Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005;14:2287-93.
33. α-Tocopherol β-Carotene Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. The α-Tocopherol, β Carotene Cancer Prevention Study Group [comment]. N Engl J Med 1994;330:1029-35.
34. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of β carotene and vitamin A on lung cancer and cardiovascular disease [comment]. N Engl J Med 1996;334:1150-5.
35. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
36. Decensi A, Bruno S, Costantini M, et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 1994;86:138-40.
37. Decensi A, Torrisi R, Bruno S, et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 2000;9:1071-8.
38. Torrisi R, Mezzetti M, Johansson H, et al. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 2000;87:601-5.
39. Camerini T, Mariani L, De Palo G, et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001;19:1664-70.
40. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000;6:2973-9.
41. Villablanca JG, Kralio MD, Ames MM, et al. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG09709). J Clin Oncol 2006;24:3423-4223.
42. Lippman SM, Lee JJ, Martin JW, et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 2006;12:3109-14.
43. Malone W, Perloff M, Crowell J, et al. Fenretinide: a prototype cancer prevention drug. Expert Opin Investig Drugs 2003;12:1829-42.
44. Clifford JL, Sabichi AL, Zou C, et al. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev 2001;10:391-5.
45. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53:6036-41.
46. Sheikh MS, Shao ZM, Li XS, et al. N-(4-hydroxyphenyl) retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995;16:2477-86.
47. Kitareewan S, Spinella MJ, Allopenna J, et al. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR-γ independent pathway. Oncogene 1999;18:5747-55.
48. Clifford JL, Menter DG, Wang M, et al. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999;59:14-8.
49. Sabichi AL, Xu H, Fischer S, et al. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res 2003;9:4606-13.
50. Kim HJ, Chakravarti N, Ordinate N, et al. N-(4-hydroxyphenyl)retinamide- induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 2006;25:2785-94.
51. Hail N, Jr., Kim JH, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006;11:1677-94.
52. Messing E, Kim KM, Sharkey F, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006;176:500-4.
53. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
54. Avritscher EBC, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006;68:549-53.
55. Sabichi AL, Lippman SM. COX-2 inhibitors and other NSAIDs in genitourinary cancer. Semin Oncol 2004;31:36-44.
56. Dinney CP, Parker C, Dong Z, et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,-5dianilinophthalimide. Clin Cancer Res 1997;3:161-8.